Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Conditions:   Glioblastoma, IDH-wildtype;   Glioblastoma;   Glioblastoma Multiforme;   Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype;   GBM Interventions:   Drug: Eflornithine (Dose Level 1);   Drug: Eflornithine (Dose Level 2);   Drug: Eflornithine (Dose Level -1);   Drug: Temozolomide Sponsor:   Orbus Therapeutics, Inc. Recruiting

Source: ClinicalTrials.gov - May 30, 2023 Category: Research Source Type: clinical trials